Company intelligence / Profile preview

Marvel King

Calgary, Alberta, Canadamarvel.com ↗

Ownership: Private
Development stage: Other

Overview

Marvel Biosciences is developing MB-204, a novel fluorinated derivative of the anti-Parkinson’s drug istradefylline targeting the adenosine A2a receptor. Preclinical studies have shown efficacy in models of Alzheimer’s disease, depression, anxiety, autism spectrum disorder, Rett syndrome and Fragile X syndrome. The company has completed cGMP synthesis and toxicology studies and is preparing for Phase 1 clinical trials.

Therapeutic areas: OncologyPsychiatryGastroenterologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Zhejiang Ausun Pharmaceutical Co., Ltd. – cGMP manufacturing partneriBrain Institute at University of Tours, France – academic collaboration on autism research

Beyond the preview

Go deeper on Marvel King.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marvel King.

Explore the full profile